Clinical Trials on Resectable Gastric and Gastroesophageal Junction Adenocarcinoma in Sweden

Total 23 results

Lund University Hospital

Active, not recruiting

Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. (INTENSE)

Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

Sweden, Norway
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Italy, United States, Spain, Ukraine, Germany, Greece, Czechia, Turkey, Belgium, Sweden, Canada
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Cancer Trials Ireland
Southampton Clinical Trials Unit; Region H Rigshospitalet; Centre Hospitalier...

Completed

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Oesophageal Cancer | Adenocarcinoma of the Oesophagus | Adenocarcinoma of the Oesophago-gastric Junction | Oesophageal Tumours | Junctional Tumours

Ireland, United Kingdom, Denmark, France, Sweden
Michael Bau Mortensen

Completed

Adjuvant PIPAC in Gastric Cancer Patients (PIPAC-OPC4)

Gastric Cancer | Gastric Adenocarcinoma

Sweden, Denmark
Lund University Hospital

Completed

Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol. (PALAESTRA)

Adenocarcinoma of the Esophagus or Esophagogastric Junction

Sweden
Karolinska University Hospital
Sahlgrenska University Hospital, Sweden; Danderyd Hospital; Blekinge County Council...

Completed

Treatment of Malignant Strictures in Esophagus and Gastroesophageal Junction With Covered or Partially Covered Stent. (StentMig)

Esophageal Cancer | Palliative Treatment | Cancer of Gastro Esophageal Junction

Sweden
Uppsala University Hospital

Recruiting

Gastric Content After 6 vs 4 Hours of Preoperative Fasting in Children (ENGUS)

Pulmonary Aspiration of Gastric Contents

Sweden
Uppsala University

Recruiting

A Multicentre Preoperative Fasting Audit (EUROFAST)

Pulmonary Aspiration of Gastric Contents

Sweden
Umeå University
Karolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaborators

Recruiting

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer (SQUARE)

Quality of Life | Surgery | Pancreas Adenocarcinoma | Chemotherapy Effect | Pancreas Cancer | Pancreas Neoplasm | Pancreas Disease | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

Sweden
Karolinska University Hospital
Ullevaal University Hospital; Oslo University Hospital; Sahlgrenska University... and other collaborators

Completed

Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia (NeoRes)

Carcinoma, Squamous Cell | Adenocarcinoma of the Esophagus and Gastric Cardia

Sweden
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

GastroEsophageal Cancer | Adenocarcinoma of the Stomach

Germany
Karolinska University Hospital
Ersta Hospital, Sweden

Completed

Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia.

Gastro Esophageal Reflux | Paraesophageal Hernia

Sweden
Erasmus Medical Center
Dutch Cancer Society; Dutch Pancreatic Cancer Group

Recruiting

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (PREOPANC-3)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Adenocarcinoma

Netherlands, Sweden, Norway
Gilead Sciences

Completed

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1)

Gastric Adenocarcinoma

Spain, United States, United Kingdom, Turkey, France, Germany, Chile, Australia, Colombia, Czechia, Belgium, Hungary, Italy, Peru, Poland, Romania
SOFAR S.p.A.

Completed

Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment

Gastro Esophageal Reflux

Germany
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
Region Stockholm

Recruiting

Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents

Bile Duct Cancer | Duodenal Cancer | Pancreatic Cancer Non-resectable | Papillary Carcinoma

Sweden
Amgen

Terminated

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)

Gastric Cancer

United States, Italy, Belgium, Hungary, Poland, Romania, Denmark, Switzerland, Canada, France, Germany, Russian Federation, Turkey, United Kingdom, Spain, Austria, Portugal, Australia, Greece, South Africa, Bulgaria, Ukraine, Brazil, ... and more
Seagen Inc.

Terminated

A Study of SGN-ALPV in Advanced Solid Tumors

Uterine Cervical Neoplasms | Stomach Neoplasms | Testicular Neoplasms | Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Gastroesophageal Junction Carcinoma

United States, Canada, Spain, Sweden, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

United States, France, Canada, Spain, Italy, Belgium, Austria, Denmark, Germany, Australia, Israel, Russian Federation, Czechia, Norway, Poland, Romania, Japan, Argentina, Ireland, Greece, United Kingdom, Brazil, Sweden, Finland
Pfizer

Completed

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (STAR-TOR)

Lymphoma, Mantle-Cell | Carcinoma, Renal Cell, Advanced | Gastrointestinal Stroma Tumors

Germany
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway

Clinical Trials on Resectable Gastric and Gastroesophageal Junction Adenocarcinoma in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations